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OBJECTIVE— To study the association between microalbuminuria and development of
preeclampsia and preterm delivery in pregnant women with type 1 diabetes.
RESEARCH DESIGN AND METHODS— This was a population-based prospective
study in 846 normoalbuminuric or microalbuminuric women with type 1 diabetes without
antihypertensive treatment in early pregnancy. Data were collected prospectively by one to three
caregivers in each center and reported to a central registry.
RESULTS— The prevalence of microalbuminuria in the first trimester was 10%, median
diabetes duration was 11 years, and third-trimester A1C was 6.6%. The frequencies of pre-
eclampsia and preterm delivery before 34 weeks in the microalbuminuric group were 40 and
13%, both significantly higher than those in the normoalbuminuric group (12 and 6%, respec-
tively, P 0.001). After adjustments for possible confounders, significant predictors for devel-
opment of preeclampsia were microalbuminuria (odds ratio 4.0 [95% CI]), nulliparity (3.1
[1.9–5.1]), and third-trimester A1C (1.3 [1.1–1.5] per 1% increase). Delivery before 34 weeks
was associated with early microalbuminuria in univariate analyses, but in multivariate analyses
A1C was the only significant predictor of this outcome. Preeclampsia was associated with a
threefold higher risk of delivery before 34 weeks.
CONCLUSIONS— The presence of microalbuminuria in early pregnancy is associated with
a fourfold increased risk of developing preeclampsia. A1C values during pregnancy are highly
predictive of both preeclampsia and preterm delivery. Future research with antihypertensive
treatment in normotensive, microalbuminuric pregnant women to prevent preeclampsia is
proposed.
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Women with type 1 diabetes andtheir offspring are at increasedrisk of development of pre-
eclampsia and preterm delivery (1). It is
well documented that the presence of di-
abetic nephropathy is associated with a
very high risk of gestational hypertension,
preeclampsia, and preterm delivery. The
forerunner of diabetic nephropathy is
characterized by urinary albumin excre-
tion between 30 and 300 mg/24 h, so-
called microalbuminuria (2,3). Whether
the presence of microalbuminuria in early
pregnancy is also associated with devel-
opment of preeclampsia has only been in-
vestigated in relatively small selected
samples (4–9), and some of these include
women with type 1, type 2, and gesta-
tional diabetes mellitus. In one center a
prevalence of preeclampsia of 40% in 26
women with type 1 diabetes and mi-
croalbuminuria has been described (9).
Others could not find an association be-
tween slightly elevated protein excretion
early in pregnancy and development of
preeclampsia (10).
In Denmark, clinical data on 1,200
pregnancies in women with type 1 diabe-
tes were collected prospectively during 7
years. The current report focuses on the
relationship between microalbuminuria
present at the first pregnancy visit and the
risk of preeclampsia and preterm delivery
in patients without preexisting use of an-
tihypertensive medication and/or diabetic
nephropathy.
RESEARCH DESIGN AND
METHODS— During 1993–1999 all
pregnancies (N  1,215) in Danish
women with type 1 diabetes were re-
ported prospectively to a central registry
in the Danish Diabetes Association (11).
The patients delivered in eight centers.
Pregnancies were registered if the dura-
tion was 24 weeks, and only the first
pregnancy during the study period was
included. Of the women, 66 with overt
diabetic nephropathy (urine albumin ex-
cretion rate [UAER] 300 mg/24 h or
200 g/min) and 30 receiving antihyper-
tensive medical treatment at the first visit
were excluded together with those with
recurrent pregnancies (n 225) and twin
pregnancies (n  24) and those with no
information on early urinary albumin to-
creatinine ratio (n  24), leaving 846
women for analysis. Hypertension was
defined as blood pressure 140/90
mmHg. The methods of the data collec-
tion were described previously (11). In
brief, information on maternal demogra-
phy, diabetes status, and pregnancy out-
come was collected prospectively with
status at predefined time points: up to 3
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months before gestation, first trimester,
second trimester, third trimester, and af-
ter delivery. Data were reported after de-
livery by one to three caregivers per
center. Microalbuminuria in early preg-
nancy was defined as microalbuminuria
before conception and/or during the first
trimester (UAER between 30 and 300
mg/24 h or between 20 and 200 g/min).
The clinical practice for instituting anti-
hypertensive treatment in pregnancy was
similar in all centers during the study pe-
riod: blood pressure of 140/90 mmHg.
All patients gave informed consent, and
the local ethics committees approved the
study. A subgroup of 25% of the mate-
rial from one center was included in a pre-
vious report (9).
Preeclampsia was defined as blood
pressure 140/90 mmHg and protein-
uria (2 on a dipstick) after 20 weeks of
gestation and preterm delivery as delivery
before 37 completed gestational weeks.
Gestational age was based on an ultra-
sound scan before 20 weeks in the major-
ity of the women; alternatively the date of
the last menstrual bleeding was used. For
further details of the clinical setting, see
Jensen et al. (11).
Statistical analysis was performed
with STATA 9.0 (StataCorp, College Sta-
tion, TX). Data are given as medians (in-
terquartile range), numbers, and per-
centages. Comparisons were made by the
Wilcoxon rank-sum test or the 2 test.
Risks of preeclampsia and preterm deliv-
ery before 34 weeks are given as odds ra-
tio (95% CI). Logistic regression analysis
was performed to determine predictors
for preeclampsia and preterm delivery:
age, BMI, preconceptional daily insulin
dose, first- and third-trimester A1C (con-
tinuous variables), and nulliparity, prolif-
erative retinopathy, blood pressure
140/90 mmHg, and microalbuminuria
at first visit/before conception (binary
variables). P  0.05 was considered sta-
tistically significant. Because the first- and
third-trimester A1C values were highly
correlated, we only inserted one of them
at the time in the multivariate models. Re-
sults are given for both models in Tables 2
and 3.
RESULTS— The women in the study
were median 28 (interquartile range 25–
32) years old and had BMI of 23 (21–25)
kg/m2 and diabetes duration of 11 (5–17)
years. Of the women, 509 (60%) were
nulliparous and first- and third-trimester
A1C values were 7.2 (6.5–8.0)% and 6.6
(6.1–7.4)%, respectively. Birth weight
and gestational age of the offspring were
3,625 (3,145–4,030) g and 260 (252–
266) days, respectively.
Of the women, 93 (10%) had mi-
croalbuminuria in early pregnancy, and
they were characterized by longer dura-
tion of diabetes, lower parity, higher BMI,
higher prevalences of proliferative reti-
nopathy, untreated hypertension at con-
ception, and higher A1C (Table 1). Of the
women with microalbuminuria, 41% (34
of 84) developed preeclampsia vs. 12%
(97 of 762) of the women with normal
UAER (P  0.001). Hypertension during
the second trimester was seen in 13% (11
of 84) of the microalbuminuric women
vs. 1.5% (11 of 762) in the normoalbu-
minuric group.
BMI, high blood pressure at concep-
tion, diabetes duration, and daily insulin
dose at conception were significantly as-
sociated with preeclampsia in the univar-
iate analyses but not in the multivariate
analysis (Table 2). A1C values during the
Table 1—Maternal and fetal characteristics in 846 normoalbuminuric and microalbuminuric
women with type 1 diabetes
Normoalbuminuria Microalbuminuria P
n 762 84
Age (years) 28 (25–32) 27 (24–31) 0.34
BMI (kg/m2) 23 (21–25) 24 (22–26) 0.002
Duration of diabetes (years) 10 (4–17) 15 (10–20) 0.001
Nulliparity 452 (59) 57 (68) 0.12
Prepregnancy insulin dose (IU/day) 44 (32–54) 47 (40–58) 0.001
Blood pressure 140/90
mmHg at first visit 5 (1) 3 (4) 0.001
Proliferative retinopathy 25 (3) 9 (11) 0.001
First-trimester A1C (%) 7.1 (6.4–8.0) 7.6 (6.8–8.5) 0.007
Third-trimester A1C (%) 6.6 (6.0–7.3) 6.8 (6.2–7.5) 0.14
Hypertension during second
trimester* 11 (1.5) 11 (13) 0.001
Preeclampsia 92 (12) 34 (41) 0.001
Gestational age (days) 260 (252–266) 260 (250–266) 0.2
Gestational age 34 weeks 45 (6) 11 (13) 0.02
Gestational age 37 weeks 284 (37) 30 (36) 0.78
Birth weight (g) 3,650 (3,162–4,060) 3,335 (2,900–3,650) 0.001
Large-for-gestational-age infant 483 (63) 42 (50) 0.02
Data are medians (interquartile range) or n (%). *Blood pressure 140/90 mmHg.
Table 2—Predictors of preeclampsia in women with type 1 diabetes: univariate and multivar-
iate logistic regression analyses
Univariate logistic
regression
Multivariate logistic
regression
OR (95% CI) P OR (95% CI) P
Age (years) 1.0 (0.9–1.0) 0.07 — —
BMI (kg/m2) 1.1 (1.0–1.1) 0.003 1.04 (1.0–1.1) 0.17
Duration of diabetes (years) 1.03 (1.01–1.05) 0.003 1.01 (1.0–1.04) 0.21
Nulliparity 2.6 (1.7–4.1) 0.001 3.1 (1.9–5.3) 0.001
Prepregnancy insulin dose
(IU/day) 1.02 (1.01–1.03) 0.001 1.01 (1.00–1.03) 0.14
Blood pressure 140/90
mmHg at first visit 5.8 (1.4–23.6) 0.011 1.0 (1.0–1.02) 0.91
Proliferative retinopathy 1.9 (0.9–4.4) 0.30 — —
First-trimester A1C (%)* 1.2 (1.0–1.3) 0.016 — —
Third-trimester A1C (%) 1.2 (1.1–1.4) 0.008 1.3 (1.1–1.5) 0.010
Microalbuminuria 5.0 (3.0–8.1) 0.001 4.0 (2.2–7.2) 0.001
*First-trimester A1C was not a significant predictor in a separate multivariate model without third-trimester
A1C (OR 1.2 95% CI 0.9–1.4	, P 0.07). ORs of microalbuminuria, nulliparity, and prepregnancy insulin
dose did not change significantly in this model.
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first and third trimesters were both posi-
tively related to the rate of preeclampsia.
Because these values correlated strongly,
we inserted only one A1C value at the
time in the multivariate models. Indepen-
dent predictors of preeclampsia were
early microalbuminuria (odds ratio [OR]
4.0 [95% CI 2.2–7.2]), nulliparity (3.1
[1.9–5.3]), and third-trimester A1C (1.3
[1.1–1.5] increase per 1%).
Neonatal outcomes in the normoalbu-
minuric versus microalbuminuric group
were hypoglycemia (intravenous glucose)
28 vs. 30% (P  0.61), perinatal mor-
tality 3 vs. 5% (P  0.26), respiratory
distress 17 vs. 19% (P  0.65), and
jaundice (phototherapy) 15 vs. 17%
(P  0.76).
The rates of preterm delivery before
37 weeks were equal in the two groups
(37 vs. 36%). Preterm delivery before 34
weeks was seen in 11% (13 of 84) of the
women with microalbuminuria and
in 6% (45 of 746) of the women with
normoalbuminuria. First- and third-
trimester A1C, microalbuminuria, and
preconceptional insulin dose were signif-
icant predictors for preterm delivery be-
fore 34 weeks in univariate analyses,
whereas only A1C remained significant in
the multivariate analyses (Table 3). Of the
very preterm deliveries, 34% (19 of 56)
were complicated by preeclampsia vs.
13% (107 of 790) among deliveries after
34 weeks (OR 3.3 [95% CI 1.8–5.9], P
0.001). Hypertension during the second
trimester was seen in 16% (9 of 55) and
2% (13 of 780), respectively (very pre-
term vs. others) (2.3 [1.7–3.1], P 
0.001).
CONCLUSIONS— Our study con-
firms that both microalbuminuria in early
pregnancy and poor glycemic control
throughout pregnancy are strongly asso-
ciated with development of preeclampsia
in women with type 1 diabetes. Thus, the
risk of preeclampsia was fourfold higher
in women with microalbuminuria com-
pared with that in normoalbuminuric
women.
Strengths and weaknesses of the
study and relation to other studies
To our knowledge, this is the largest
prospective national population-based
study of unselected pregnant women
with type 1 diabetes with detailed infor-
mation on glycemic control and mi-
croangiopathic complications in early
pregnancy. The large sample size and
homogeneity of the population give a
good estimate of the incidence of pre-
eclampsia in pregnant women with type
1 diabetes. For comparison, the rate of
preeclampsia in the background popu-
lation was 2.6% (11).
Of the women with microalbumin-
uria, 25% were also included in the study
of Ekbom et al. (9), but the majority of the
remaining 75% of women with mi-
croalbuminuria came from seven other
centers without any special focus on mi-
croalbuminuria. Thus, the bias of this
study is considered to be relatively small
because the overall incidence of pre-
eclampsia was the same. Furthermore, the
clinical practice for instituting antihyper-
tensive treatment in pregnancy was simi-
lar in all centers during the study period.
Another weakness of our study was that
eight different centers contributed to the
register. It could be argued that a number
of women may have type 2 diabetes, as no
data were recorded on C-peptide or islet
cell immune markers. However, women
entering the study were all judged to have
type 1 diabetes by their caregivers and
were receiving insulin treatment before
conception, the majority were of normal
weight, and the mean diabetes duration
was 11 years. During the study period,
both severe childhood obesity and type 2
diabetes among young women were un-
common in Caucasian Danish women.
It is well known that the presence of
diabetic nephropathy leads to an even
higher rate of preeclampsia (1,9) and that
antihypertensive treatment reduces uri-
nary albumin excretion and thereby con-
founds the data (12,13). Women with
diabetic nephropathy and women receiv-
ing antihypertensive treatment without
any signs of diabetic nephropathy were
therefore excluded. Measurements of uri-
nary albumin excretion in women with
diabetes are now generally preferred
among diabetologists, whereas measure-
ments of small amounts of protein are not
widely used. Incidental detection of small
amounts of protein in the urine is fre-
quently seen. In addition, urinary albu-
min excretion does not change during
normal pregnancy, whereas an increase in
protein excretion can be demonstrated
(1). This fact may explain why a study
using urinary protein excretion could not
demonstrate that a slightly increased level
was associated with increased risk of pre-
eclampsia (10).
Meaning of the study
The study highlights a significant clinical
problem and calls for improved clinical
practice in this group of patients. Our
finding of an association between meta-
bolic control and development of pre-
eclampsia is in accordance with previous
findings from Scandinavia (14,15). Both
high levels of A1C early in pregnancy and
a suboptimal decrease in A1C during
pregnancy are associated with develop-
ment of preeclampsia (16). A decrease in
A1C of at least 0.5% during pregnancy
and an upper normal limit of 5.6% in late
pregnancy have been described in the
normal population of pregnant women
(17). Strict metabolic control aiming
for A1C near the upper normal limit in
pregnancy of women with a high risk of
development of preeclampsia thus seems
justified.
In nonpregnant normotensive pa-
tients with type 1 diabetes and microalbu-
minuria, antihypertensive treatment with
an ACE inhibitor improves the long-term
prognosis by postponing the progression
to overt nephropathy (18). Furthermore,
data suggest that treatment with an ACE
inhibitor before pregnancy has beneficial
effects on maternal renal function during
pregnancy and overall pregnancy out-
come (12). However, in pregnancy, expo-
sure to ACE inhibitors and angiotensin II
receptor blockers has been associated
Table 3—Predictors of delivery before gestational week 34 in women with type 1 diabetes:
univariate and multivariate logistic regression analyses
Univariate logistic
regression
Multivariate logistic
regression
OR (95% CI) P OR (95% CI) P
Prepregnancy insulin dose (IU/day) 1.01 (1.00–1.03) 0.045 1.01 (0.99–1.03) 0.32
First-trimester A1C (%)* 1.3 (1.1–1.5) 0.010
Third-trimester A1C (%) 1.5 (1.1–1.9) 0.003 1.6 (1.2–2.0) 0.003
Microalbuminuria 2.4 (1.2–4.8) 0.015 1.6 (0.6–4.0) 0.34
*First-trimester A1C was a significant predictor in a separate multivariate model without third-trimester A1C
(OR 1.3 95% CI 1.1–1.6	, P  0.004).
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with fetal complications including con-
genital malformations (19,20). Thus,
treatment with ACE inhibitors or angio-
tensin receptor blockers should be dis-
continued before conception or as soon as
pregnancy is suspected and replaced by
alternative antihypertensive drugs with
careful monitoring of blood pressure and
UAER. In the present study, other antihy-
pertensive agents were initiated only if
blood pressure exceeded 140/90 mmHg.
This situation often occurred at the time
when preeclampsia was diagnosed in
these women, and the majority of the
women in this study were therefore not
treated with antihypertensive medication
until preeclampsia actually developed.
The beneficial effect of antihypertensive
treatment based on methyldopa or labe-
talol in normotensive women with
microalbuminuria has been suggested
(13,21). Applying intensive antihyper-
tensive treatment from the early phase of
pregnancy in woman with microalbumin-
uria seems to reduce the risk of pre-
eclampsia leading to preterm delivery
(21). Our data on microalbuminuria and
second-trimester hypertension might in-
dicate that a rise in blood pressure was
preceded by microalbuminuria. On the
other hand, data were not collected with
this purpose, and we cannot draw firm
conclusions on this point.
We found a higher frequency of pre-
term delivery before 34 weeks in the mi-
croalbuminuric group. After adjustment
for confounders, early microalbuminuria
was not a significant predictor whereas
both first- and third-trimester A1C re-
mained highly predictive. A possible ex-
planation is the association between
microalbuminuria and glycemic control,
thus indicating that the relationship with
preterm delivery of the former may have
been underestimated. Another issue is the
small number at risk, which may lead to
type 2 error. As expected, preeclampsia
was associated with delivery before 34
weeks. Our dataset cannot provide more
details concerning this association, but it
is likely that the presence of preeclampsia
led to indicated preterm delivery. Pre-
eclampsia, pregnancy-induced hyperten-
sion, and preterm delivery might be part
of the same disease complex: both
second-trimester hypertension and pre-
eclampsia were highly associated with
very preterm delivery. However, adding
these components to the multivariate
model did not markedly change the
strength of other predictors. These asso-
ciations should be investigated prospec-
tively with data collection focusing on the
precise onset of the rise in blood pressure
and/or UACR and more clinical details on
the preterm delivery.
In contrast to our previous study (9),
we did not identify microalbuminuria as a
significant predictor of preterm delivery
before 37 weeks. This result may be ex-
plained by a less precise recording of mi-
croalbuminuria in the present study or
the fact that women with antihyperten-
sive treatment or overt nephropathy were
excluded from our analysis. Another pos-
sibility is that almost 50% of the women
delivered preterm, partly due to routine
procedures followed at that time. Still,
preterm delivery before week 34 might
have a more profound adverse effect on
the infant than preterm delivery before 37
weeks and is therefore clinically relevant.
Unanswered questions and
proposals for future research
The results of this study underline the
need for identification and treatment of
women with microalbuminuria and poor
glycemic control in early pregnancy. So
far, the primary focus has been on glyce-
mic control, but observational studies in-
dicate that more aggressive antihyper-
tensive treatment in normotensive,
microalbuminuric women with type 1 di-
abetes may reduce the risk of develop-
ment of preeclampsia with no apparent
adverse effect on pregnancy outcome
(13,21). These findings should be con-
firmed in large-scale prospective random-
ized studies.
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